Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
MedCity News
Digital therapeutics platform Happify Health raises $73M
Happify Health, a startup building digital health tools, raised $73 million in funding. The company plans to use the funds to build out more specialized solutions for health plans and pharma companies.
Shares0
Happify, a startup building a self-care platform, raised $73 million in funding. Photo credit: Happify Health
Digital therapeutics startup Happify Health raised $73 million in funding. The New York-based company builds app-based tools based on cognitive behavioral therapy and mindfulness.
Deerfield Management Company led the series D round, with participation from Omega Capital Partners, ION Crossover Partners and existing investors. Happify plans to use the funds to build out more specialized solutions for health plan and pharmaceutical companies.
Dr. Michael Daignault
Michael Daignault, MD, is a board-certified emergency physician in Los Angeles. He is Chief Medical Advisor with Reliant Health Services. Dr. Daignault is also a Covid-19 medical expert for ABC7 news and has consulted on medical news segments for CBSLA News, Inside Edition, and KNX1070 news radio. He promotes evidence-based public health information thru weekly posts on his Instagram account, @drdaignault. Dr. Daignault studied Global Health at Georgetown University and has a Medical Degree from the joint Ben-Gurion University/Columbia Medical Center Medical School for International Health. He did his residency training in Emergency Medicine at Lincoln Medical Center in the South Bronx, New York City. Dr. Daignault is a former United States Peace Corps Volunteer and has worked for Médecins Sans Frontieres (Doctors Without Borders). He is an avid rock climber and surfer.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
MedCity News
Melinta antibiotic for MRSA & other serious skin infections wins FDA approval
Melinta Therapeutics already sells an antibiotic for serious skin infections. But FDA approval of Kimyrsa gives clinicians another option to offer patients, one with more convenient dosing.
Shares0
Melinta Therapeutics can now add another antibiotic to its portfolio after the FDA on Monday approved the company’s infused treatment for serious skin infections such as MRSA.
Approval of oritavancin, which will be marketed under the name Kimyrsa, covers the treatment of acute bacterial skin and skin structure infections (ABSSSI). The New Haven, Connecticut-based company already sells another oritavancin-based product, Orbactiv. But Kimyrsa will offer the prospect of a single, one-hour infusion compared to Orbactiv, which is infused over the course of three hours. Approved in 2014, Orbactiv was developed as an alternative to vancomycin, an antibiotic that is infused twice daily for sev